AAPL vs. AZN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AAPL and AZN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
AAPL’s market capitalization of 3,189.54 billion USD is substantially larger than AZN’s 430.65 billion USD, indicating a significant difference in their market valuations.
AAPL’s beta of 1.21 points to significantly higher volatility compared to AZN (beta: 0.17), suggesting AAPL has greater potential for both gains and losses relative to market movements.
AZN is an American Depositary Receipt (ADR), allowing U.S. investors direct exposure to its non-U.S. operations. AAPL, on the other hand, is a domestic entity.
| Symbol | AAPL | AZN |
|---|---|---|
| Company Name | Apple Inc. | AstraZeneca PLC |
| Country | US | GB |
| Sector | Technology | Healthcare |
| Industry | Consumer Electronics | Drug Manufacturers - General |
| CEO | Timothy D. Cook | Pascal Claude Roland Soriot |
| Price | 213.55 USD | 69.45 USD |
| Market Cap | 3,189.54 billion USD | 430.65 billion USD |
| Beta | 1.21 | 0.17 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | December 12, 1980 | May 12, 1993 |
| ADR | No | Yes |
Historical Performance
This chart compares the performance of AAPL and AZN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
AAPL
151.31%
Consumer Electronics Industry
- Max
- 14.30%
- Q3
- 14.30%
- Median
- 5.13%
- Q1
- -15.88%
- Min
- -27.23%
AAPL’s Return on Equity of 151.31% is exceptionally high, placing it well beyond the typical range for the Consumer Electronics industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
AZN
19.18%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
AZN’s Return on Equity of 19.18% is on par with the norm for the Drug Manufacturers - General industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
AAPL
47.30%
Consumer Electronics Industry
- Max
- 4.18%
- Q3
- 4.18%
- Median
- 4.09%
- Q1
- -0.34%
- Min
- -0.34%
AAPL’s Return on Invested Capital of 47.30% is exceptionally high, placing it well beyond the typical range for the Consumer Electronics industry. This demonstrates an outstanding ability to deploy capital efficiently and create significant value.
AZN
10.93%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
AZN’s Return on Invested Capital of 10.93% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
AAPL
24.30%
Consumer Electronics Industry
- Max
- 24.30%
- Q3
- 8.81%
- Median
- 8.10%
- Q1
- -4.74%
- Min
- -7.22%
A Net Profit Margin of 24.30% places AAPL in the upper quartile for the Consumer Electronics industry, signifying strong profitability and more effective cost management than most of its peers.
AZN
14.14%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
AZN’s Net Profit Margin of 14.14% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
AAPL
31.81%
Consumer Electronics Industry
- Max
- 31.81%
- Q3
- 16.77%
- Median
- 10.95%
- Q1
- -0.21%
- Min
- -4.78%
An Operating Profit Margin of 31.81% places AAPL in the upper quartile for the Consumer Electronics industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
AZN
19.21%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
AZN’s Operating Profit Margin of 19.21% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | AAPL | AZN |
|---|---|---|
| Return on Equity (TTM) | 151.31% | 19.18% |
| Return on Assets (TTM) | 29.37% | 7.31% |
| Return on Invested Capital (TTM) | 47.30% | 10.93% |
| Net Profit Margin (TTM) | 24.30% | 14.14% |
| Operating Profit Margin (TTM) | 31.81% | 19.21% |
| Gross Profit Margin (TTM) | 46.63% | 81.41% |
Financial Strength
Current Ratio
AAPL
0.82
Consumer Electronics Industry
- Max
- 0.82
- Q3
- 0.82
- Median
- 0.70
- Q1
- 0.64
- Min
- 0.63
AAPL’s Current Ratio of 0.82 aligns with the median group of the Consumer Electronics industry, indicating that its short-term liquidity is in line with its sector peers.
AZN
0.90
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
AZN’s Current Ratio of 0.90 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
AAPL
1.47
Consumer Electronics Industry
- Max
- 2.23
- Q3
- 1.47
- Median
- 0.80
- Q1
- 0.51
- Min
- 0.16
AAPL’s Debt-to-Equity Ratio of 1.47 is typical for the Consumer Electronics industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
AZN
0.77
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
AZN’s Debt-to-Equity Ratio of 0.77 is typical for the Drug Manufacturers - General industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
AAPL
--
Consumer Electronics Industry
- Max
- 14.74
- Q3
- 8.73
- Median
- 3.32
- Q1
- -40.43
- Min
- -114.16
Interest Coverage Ratio data for AAPL is currently unavailable.
AZN
7.95
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
AZN’s Interest Coverage Ratio of 7.95 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | AAPL | AZN |
|---|---|---|
| Current Ratio (TTM) | 0.82 | 0.90 |
| Quick Ratio (TTM) | 0.78 | 0.70 |
| Debt-to-Equity Ratio (TTM) | 1.47 | 0.77 |
| Debt-to-Asset Ratio (TTM) | 0.30 | 0.30 |
| Net Debt-to-EBITDA Ratio (TTM) | 0.50 | 1.49 |
| Interest Coverage Ratio (TTM) | -- | 7.95 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for AAPL and AZN. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
AAPL
0.47%
Consumer Electronics Industry
- Max
- 1.88%
- Q3
- 0.53%
- Median
- 0.50%
- Q1
- 0.00%
- Min
- 0.00%
AAPL’s Dividend Yield of 0.47% is consistent with its peers in the Consumer Electronics industry, providing a dividend return that is standard for its sector.
AZN
1.87%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
AZN’s Dividend Yield of 1.87% is in the lower quartile for the Drug Manufacturers - General industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio
AAPL
15.74%
Consumer Electronics Industry
- Max
- 98.30%
- Q3
- 15.74%
- Median
- 10.10%
- Q1
- 0.00%
- Min
- 0.00%
AAPL’s Dividend Payout Ratio of 15.74% is within the typical range for the Consumer Electronics industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
AZN
63.60%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
AZN’s Dividend Payout Ratio of 63.60% is within the typical range for the Drug Manufacturers - General industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | AAPL | AZN |
|---|---|---|
| Dividend Yield (TTM) | 0.47% | 1.87% |
| Dividend Payout Ratio (TTM) | 15.74% | 63.60% |
Valuation
Price-to-Earnings Ratio
AAPL
32.91
Consumer Electronics Industry
- Max
- 51.71
- Q3
- 41.35
- Median
- 30.99
- Q1
- 25.46
- Min
- 19.94
AAPL’s P/E Ratio of 32.91 is within the middle range for the Consumer Electronics industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
AZN
28.12
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
At 28.12, AZN’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Drug Manufacturers - General industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Forward P/E to Growth Ratio
AAPL
3.79
Consumer Electronics Industry
- Max
- 7.16
- Q3
- 5.62
- Median
- 3.99
- Q1
- 2.77
- Min
- 2.43
The Forward PEG Ratio is often not a primary valuation metric in the Consumer Electronics industry.
AZN
2.56
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
AZN’s Forward PEG Ratio of 2.56 is within the middle range of its peers in the Drug Manufacturers - General industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
AAPL
7.97
Consumer Electronics Industry
- Max
- 7.50
- Q3
- 4.17
- Median
- 1.76
- Q1
- 0.88
- Min
- 0.16
With a P/S Ratio of 7.97, AAPL trades at a valuation that eclipses even the highest in the Consumer Electronics industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
AZN
3.98
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
AZN’s P/S Ratio of 3.98 aligns with the market consensus for the Drug Manufacturers - General industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
AAPL
47.94
Consumer Electronics Industry
- Max
- 3.36
- Q3
- 3.36
- Median
- 2.83
- Q1
- 2.78
- Min
- 2.78
At 47.94, AAPL’s P/B Ratio is at an extreme premium to the Consumer Electronics industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
AZN
5.33
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
Valuation at a Glance
| Symbol | AAPL | AZN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 32.91 | 28.12 |
| Forward PEG Ratio (TTM) | 3.79 | 2.56 |
| Price-to-Sales Ratio (P/S, TTM) | 7.97 | 3.98 |
| Price-to-Book Ratio (P/B, TTM) | 47.94 | 5.33 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 32.39 | 22.59 |
| EV-to-EBITDA (TTM) | 23.47 | 13.82 |
| EV-to-Sales (TTM) | 8.14 | 4.46 |